Ionis Pharmaceuticals Inc. (NASDAQ:IONS) went up by 0.98% during the previous trading session, and it is maintaining the win ahead of Thursday’s trading session. The share price of the Biotechnology giant went up by $60.79 to trade ended Thursday trading at $60.20. This is up from the $60.2 price recorded on Wednesday’s trading session. Thanks to this latest performance, IONS is closer to the higher price 52-week target of $120.00 and further from the lowest price target of $19.00. Its performance from the start of the year has also been positive, with IONS up by 0.63% year-to-date.
Ionis Pharmaceuticals Inc. (IONS) started the day trading at $61 and recorded an intraday high of $61.75. It also recorded an intraday low of $60.228 during Thursday’s trading session. Ionis Pharmaceuticals Inc. is a very active stock that recorded a trading volume that is less than -40.29% of the average daily trading volume on Thursday. The stock’s trading volume on Thursday was 611833, which is less than -40.29 of the total average daily trading volume of 858.36K.
Ionis Pharmaceuticals Inc. (NASDAQ:IONS) 2020 Performance Impressive
The increase in IONS’s stock price on Thursday saw its overall performance boost over the past few months. We can quantify the performance of the stock so far this year using a few metrics. The 52-week high price of IONS currently stands at $73.09, which is higher than the current trading price of the stock by 16.83%. However, IONS’s current trading price is -54.6% lower than the 52-week low price of $39.32. In terms of trading volume, Ionis Pharmaceuticals Inc. currently experienced healthy participation during the last trading session. 611833 shares of Ionis Pharmaceuticals Inc. were traded on the stock exchange on Thursday, which is less than -40.29% of the 858.36K average trading volume of the stock.
The performance of the stock has been positive over the past year. IONS’s performance over the past one year has seen it plunge by -7.28%, while the stock has gone down by -0.16% in the last six months. The quarterly performance of IONS currently stands at 24.04%, and it is up by 6.99% in the last month. The only negative figure was from the weekly performance, which currently reads -0.43%. At the time of writing IONS’s report, the company has a total market cap of $8.39B, making it one of the largest publicly-traded companies in the world.Ionis Pharmaceuticals Inc. also has over 817 employees all over the world.
IONS Insider Activities
For Ionis Pharmaceuticals Inc., insiders hold 86.80% of all company shares. The insider transactions over the past six months are up by 0.60%. During that period, insiders bought 193,709 shares in 20 transactions. In that same period, insiders sold 187,611 of their shares in 27 transactions. After these transactions, insiders at Ionis Pharmaceuticals Inc. now hold 6.98M shares, which is over 87.93% of the total company stocks. Institutional investors currently hold a large chunk of the IONS shares, as they control 5.01% of the company’s total stock.
IONS Fundamental Analysis
For Ionis Pharmaceuticals Inc., the stock’s diluted earnings per share (EPS) stands at 1.12. In the coming year, analysts expect the EPS to be -0.17. The stock’s EPS growth this year is 572.90%, with analysts expecting almost a 1 growth in the earnings per share next week. In terms of revenue, Ionis Pharmaceuticals Inc.’s quarterly sales (YOY) is shrinking at -0.22, which is lower than the average annual revenue of 52.40% over the past half a decade.
The Return on Investment (ROI) on Ionis Pharmaceuticals Inc.’s stock currently stands at 13.40%, and it has a net profit margin of 16.80%. The operating margin of the company is 16.80%, and its gross margin is 99.40%.
IONS Analysts Prediction
Analysts at Morgan Stanley believe that IONS is Underweight, and they have a price target of between $63 and $48. BofA/Merrill and Laidlaw also believe that Ionis Pharmaceuticals Inc.’s stock is outperforming at the moment.
At the moment, Ionis Pharmaceuticals Inc.’s Total Debt to Equity ratio stands at 0.59, and they have a long-term Debt to Equity ratio of 0.58.
IONS Technical Analysis
The Simple Moving Average (SMA) is one of the most powerful technical indicators. The 20-day Simple Moving Average of IONS currently stands at 3.99%, while the SMA50 is 6.98%. The biggest one is the SMA200, which is currently reading 6.19% ahead of Thursday’s trading session. The Relative Strength Index of this stock is 58.53, while its price to earnings ratio (P/E) is 54.28.